GlassScriptPhysician profile
Vi L Phan
NPI 1386287514
$4,655.27
in general payments reported to CMS, 2019-2025
29 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $508 · 2022: $311 · 2023: $636 · 2024: $1,707 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,587 · Travel and Lodging: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,587.36 |
| Travel and Lodging | $249.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,302.93 | 2023-2025 | Cardiomems |
| Amgen INC. | $568.94 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $403.17 | 2021-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $385.77 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $191.40 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $179.96 | 2021-2025 | |
| Esperion Therapeutics, INC. | $177.69 | 2022-2025 | Nexletol |
| Edwards Lifesciences Corporation | $172.42 | 2021-2024 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $164.33 | 2022-2025 | Wegovy, Ozempic |
| Bridgebio Pharma, INC. | $159.32 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $151.02 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $138.55 | 2023-2025 | Onpattro, Amvuttra |
| Regeneron Healthcare Solutions, INC. | $117.36 | 2024 | Evkeeza, Praluent |
| Medtronic, INC. | $71.41 | 2023 | Endurant Iis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.63 | 2022-2024 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $48.23 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $48.20 | 2023-2025 | Verquvo |
| Astellas Pharma US INC | $44.28 | 2021 | |
| Biotronik INC. | $41.31 | 2021 | |
| Scpharmaceuticals INC. | $35.01 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $30.87 | 2023-2024 | Inpefa |
| Cvrx, INC. | $24.83 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $23.14 | 2022 | |
| Tactile Systems Technology INC | $22.12 | 2024 | Entre Plus, Flexitouch Plus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.45 | 2023 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $19.00 | 2022 | |
| Glaxosmithkline, LLC. | $17.17 | 2025 | Arexvy, Shingrix |
| Kiniksa Pharmaceuticals, LTD. | $13.84 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vi Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.